portal
  Home About us Reports Charts News Custom Company Scan  
Report Charts News
*
Title Content
Economy&Goods
  Economy
  ConsumerGoods
  Food&Beverage
  Agriculture
Life Sciences
  Biotechnology
  Medical
  Pharmaceutical
Manufacturing
  Automotive
  Chemical
  Energy
  Machinery
  Material
  Metals & Minerals
Public Sector
  Environment
  Finance Service
  Infrastructure
  Logistics
  Real Estate
  Retailing
  Tourism
  Training
Technology And Media
  Electronics
  Internet
  Hardware
  Media
  Software
  Telecommunications

Tel: 0086-10-82600828
Fax: 0086-10-82601570
Email:


 Lilly to pump in $350 million in China to boost insulin making capacity
 
CreateTime:2013-11-15 Editor:liaoyan
Text Size:       
 

Eli Lilly and Co said it will invest more than $700 million to boost its insulin manufacturing capacity in Puerto Rico, France, China and the United States.

The company's traditional stronghold has been its diabetes treatments, but the sales of its drugs have been suffering due to increasing competition from companies including Denmark's Novo Nordisk.

Lilly said on Thursday it will invest $350 million in China, which already has the most diabetics globally and where the number is expected to rise to 142.7 million in 2035 from 98.4 million.


Related Reports
China Animal Vaccine Industry Report, 2019-2025
China Blood Product Industry Report, 2020-2026
China Vacuum Blood Collection Device Industry Report, 2019-2025
China Human Vaccine Industry Report, 2019-2025
China Independent Clinical Laboratory Industry Report, 2019-2025
2005-2021 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1